✉ info@591daili.com☎ +86-18553102138
📞 WhatsApp中文
591daili 济南圣和化工
Home › Product Catalog › 4-Hydroxypyrazolo[3,4-d]pyrimidine

4-Hydroxypyrazolo[3,4-d]pyrimidine

CAS 315-30-0C5H4N4OMW 136.11

4-Hydroxypyrazolo[3,4-d]pyrimidine (CAS 315-30-0) — formula C5H4N4O, molecular weight 136.11; category organic chemicals.

Specifications

CAS Number315-30-0
Molecular FormulaC5H4N4O
Molecular Weight136.11
Melting Point>300
Boiling Point250.36
LogP-1.8
ApplicationsUses: MEDICATION, MEDICATION (Vet):, THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout, antiurolithic., Use (kg) in Switzerland (2009): >5000, Use (kg, approx.) in Germany (2009): >100000, Use (kg) in USA (2002): 59900, Use (kg) in France (2004): 54247, Consumption (g per capita) in Switzerland (2009): 0.64, Consumption (g per capita, approx.) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.21, Consumption (g per capita) in France (2004): 0.9, Excretion rate: 0.28, Calculated removal (%): 75.1, For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi., Methods of Manufacturing: Reaction of malononitrile and triethyl orthoformate to form ethoxymethylene malononitrile which is reacted with hydrazine, hydrolyzed, and condensed with formamide., (Ethoxymethylene)malononitrile is reacted with hydrazine hydrate via deethanolation and addition thus cyclizing to form 3-aminopyrazole-4-carbonitrile. Controlled hydration of nitrile forms the corresponding carboxamide which, on condensation with formamide, yields allopurinol., Formulations, Preparations: Allopurinol Preparations: (AHFS, 2009), Table: Allopurinol Preparations: (AHFS, 2009) [Table#4346], Oral Tablets, 100 mg, Lopurin (scored), Boots, Zyloprim (with povidone, scored), Burroughs Wellcome, 300 mg, Burroughs Wellcome., Tablets, 100 and 300 mg, Consumption Patterns: Essentially 100% as a uricosuric agent, U.S. Production: (1977) Probably > 4.54 x 10+5 g, (1978) Probably > 4.54 x 10+5 g, Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#4347], [US EPA, Non-confidential Production Volume Information Submitted by Companies for Chemicals Under the 1986-2002 Inventory Update Rule (IUR). 4H-Pyrazolo, General Manufacturing Information: 4H-Pyrazolo[3, 4-d]pyrimidin-4-one, 1, 5-dihydro-: ACTIVE
CategoryOrganic Chemicals

Where it is used

Documented applications: Uses: MEDICATION, MEDICATION (Vet):, THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout, antiurolithic., Use (kg) in Switzerland (2009): >5000, Use (kg, approx.) in Germany (2009): >100000, Use (kg) in USA (2002): 59900, Use (kg) in France (2004): 54247, Consumption (g per capita) in Switzerland (2009): 0.64, Consumption (g per capita, approx.) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.21, Consumption (g per capita) in France (2004): 0.9, Excretion rate: 0.28, Calculated removal (%): 75.1, For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi., Methods of Manufacturing: Reaction of malononitrile and triethyl orthoformate to form ethoxymethylene malononitrile which is reacted with hydrazine, hydrolyzed, and condensed with formamide., (Ethoxymethylene)malononitrile is reacted with hydrazine hydrate via deethanolation and addition thus cyclizing to form 3-aminopyrazole-4-carbonitrile. Controlled hydration of nitrile forms the corresponding carboxamide which, on condensation with formamide, yields allopurinol., Formulations, Preparations: Allopurinol Preparations: (AHFS, 2009), Table: Allopurinol Preparations: (AHFS, 2009) [Table#4346], Oral Tablets, 100 mg, Lopurin (scored), Boots, Zyloprim (with povidone, scored), Burroughs Wellcome, 300 mg, Burroughs Wellcome., Tablets, 100 and 300 mg, Consumption Patterns: Essentially 100% as a uricosuric agent, U.S. Production: (1977) Probably > 4.54 x 10+5 g, (1978) Probably > 4.54 x 10+5 g, Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#4347], [US EPA, Non-confidential Production Volume Information Submitted by Companies for Chemicals Under the 1986-2002 Inventory Update Rule (IUR). 4H-Pyrazolo, General Manufacturing Information: 4H-Pyrazolo[3, 4-d]pyrimidin-4-one, 1, 5-dihydro-: ACTIVE.

Purchase Profile

What this product is

4-Hydroxypyrazolo[3,4-d]pyrimidine is a carbon-based organic compound with CAS registry number 315-30-0 and molecular formula C5H4N4O (molecular weight 136.11), belonging to the organic chemicals segment of chemical raw materials.

Identification

CAS number: 315-30-0

Its molecular formula C5H4N4O comprises 5 C, 4 H, 4 N, 1 O atoms.

Also known as: 4-Hydroxypyrazolo[3,4-d]pyrimidine · Allopurinol

Category: organic chemicals

Frequently Asked Questions

What is the CAS number of 4-Hydroxypyrazolo[3,4-d]pyrimidine?

The CAS registry number of 4-Hydroxypyrazolo[3,4-d]pyrimidine is 315-30-0.

What is the molecular formula and molecular weight of 4-Hydroxypyrazolo[3,4-d]pyrimidine?

Molecular formula C5H4N4O, molecular weight 136.11.

What other names is 4-Hydroxypyrazolo[3,4-d]pyrimidine known by?

It is also registered under: 4-Hydroxypyrazolo[3,4-d]pyrimidine, Allopurinol.

What are the documented applications of 4-Hydroxypyrazolo[3,4-d]pyrimidine?

Recorded applications: Uses: MEDICATION, MEDICATION (Vet):, THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout, antiurolithic., Use (kg) in Switzerland (2009): >5000, Use (kg, approx.) in Germany (2009): >100000, Use (kg) in USA (2002): 59900, Use (kg) in France (2004): 54247, Consumption (g per capita) in Switzerland (2009): 0.64, Consumption (g per capita, approx.) in Germany (2009): 1.2, Consumption (g per capita) in the USA (2002): 0.21, Consumption (g per capita) in France (2004): 0.9, Excretion rate: 0.28, Calculated removal (%): 75.1, For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi., Methods of Manufacturing: Reaction of malononitrile and triethyl orthoformate to form ethoxymethylene malononitrile which is reacted with hydrazine, hydrolyzed, and condensed with formamide., (Ethoxymethylene)malononitrile is reacted with hydrazine hydrate via deethanolation and addition thus cyclizing to form 3-aminopyrazole-4-carbonitrile. Controlled hydration of nitrile forms the corresponding carboxamide which, on condensation with formamide, yields allopurinol., Formulations, Preparations: Allopurinol Preparations: (AHFS, 2009), Table: Allopurinol Preparations: (AHFS, 2009) [Table#4346], Oral Tablets, 100 mg, Lopurin (scored), Boots, Zyloprim (with povidone, scored), Burroughs Wellcome, 300 mg, Burroughs Wellcome., Tablets, 100 and 300 mg, Consumption Patterns: Essentially 100% as a uricosuric agent, U.S. Production: (1977) Probably > 4.54 x 10+5 g, (1978) Probably > 4.54 x 10+5 g, Production volumes for non-confidential chemicals reported under the Inventory Update Rule. [Table#4347], [US EPA, Non-confidential Production Volume Information Submitted by Companies for Chemicals Under the 1986-2002 Inventory Update Rule (IUR). 4H-Pyrazolo, General Manufacturing Information: 4H-Pyrazolo[3, 4-d]pyrimidin-4-one, 1, 5-dihydro-: ACTIVE.

Which category does 4-Hydroxypyrazolo[3,4-d]pyrimidine belong to?

Category: Organic Chemicals.

PubChem Public Data

Public-database records for 4-Hydroxypyrazolo[3,4-d]pyrimidine (CAS 315-30-0), reproduced here for independent cross-checking.

Safety classification and hazard statements

Reported hazard statementsH301 (53.1%), H317 (94.4%)

H301 (53.1%): Toxic if swallowed [Danger Acute toxicity, oral]

H317 (94.4%): May cause an allergic skin reaction [Warning Sensitization, Skin]

Physical description and handling notes

  • 4-hydroxypyrazolo(3,4-d)pyrimidine is an odorless tasteless white microcrystalline powder. (NTP, 1992)
  • Solid
  • FLUFFY WHITE TO OFF-WHITE POWDER
  • Crystals
  • SLIGHT
  • TASTELESS

Reported physical properties

沸点250.36
熔点>300
熔点350 °C
溶解度In water, 569 mg/L at 25 °C
溶解度5.88e+00 g/L
LogP-1.8
LogPlog Kow = -0.55
LogP-1
LogP-0.55
Dissociation Constants10.2 (at 25℃)

How this substance is indexed

CAS Registry Number315-30-0
PubChem CID135401907
分子式C5H4N4O
IUPAC 名称1,5-dihydropyrazolo[5,4-d]pyrimidin-4-one
UNII(FDA)63CZ7GJN5I

Documented uses

  • THERAPEUTIC CATEGORY: Treatment of hyperuricemia and chronic gout, antiurolithic.
  • Use (kg) in Switzerland (2009): >5000
  • Use (kg; approx.) in Germany (2009): >100000
  • Use (kg) in France (2004): 54247
  • Consumption (g per capita) in Switzerland (2009): 0.64
  • Consumption (g per capita; approx.) in Germany (2009): 1.2

Names this substance appears under

allopurinol; 315-30-0; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol; Zyloric; Suspendol; Takanarumin; Allopur; Bloxanth; Uriprim; Xanturat; Urbol; Ketobun-A; Nektrohan; Adenock; Aluline; Dabrosin

Computed molecular descriptors

分子量136.11
XLogP3-0.7
氢键供体数2
氢键受体数3
可旋转键数0
精确质量136.03851076
单同位素质量136.03851076
拓扑极性表面积70.1
重原子数10
形式电荷0

Database abstract

4-Hydroxypyrazolo[3,4-d]pyrimidine · CAS 315-30-0 · C5H4N4O. UNII 63CZ7GJN5I. 沸点: 250.36; 熔点: >300; 熔点: 350 °C.

Source: PubChem / Wikidata; the batch COA governs where values differ.

You may also need

Get a quote for 4-Hydroxypyrazolo[3,4-d]pyrimidine

Supplier: Jinan Shenghe Chemical Co., Ltd. · Reply within one business day.

Email Inquiry WhatsApp
鲁ICP备19031700号-1